Evidence map›Paper›PMID 24608040›Full record

ArticleNature immunology2014

A role for the ITAM signaling module in specifying cytokine-receptor functions.

Jelena S Bezbradica, Rachel K Rosenstein, Richard A DeMarco, Igor Brodsky, Ruslan Medzhitov

Open access · greenAbstract read
In one paragraph

Article in Nature immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. The uric acid crystal receptor Clec12A potentiates type I interferon responses.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. New insights into basophil heterogeneity.Seminars in immunopathology · 2016
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Jelena S BezbradicaHoward Hughes Medical Institute and Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.
Rachel K RosensteinHoward Hughes Medical Institute and Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.
Richard A DeMarcoAmnis at EMD Millipore, Seattle, Washington, USA.
Igor Brodsky1] Howard Hughes Medical Institute and Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA. [2] Present address: Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Ruslan MedzhitovHoward Hughes Medical Institute and Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.
Howard Hughes Medical Institute · USYale University · USMilliman (United States) · US

Funding

Yale Rheumatic Diseases Research Core CenterP30AR053495 · NIAMS · YALE UNIVERSITY · PI SHLOMCHIK, WARREN D · 2007 to 2017
$7.0M
Cell Biology of TLR Signal TransductionR37AI046688 · NIAID · YALE UNIVERSITY · PI MEDZHITOV, RUSLAN · 2006 to 2015
$3.8M
Toll Pathway & Control of Adaptive Immune ResponsesR01AI055502 · NIAID · YALE UNIVERSITY · PI MEDZHITOV, RUSLAN · 2003 to 2013
$3.7M
TLRs in Host Commensal InteractionsR01DK071754 · NIDDK · YALE UNIVERSITY · PI MEDZHITOV, RUSLAN · 2007 to 2014
$2.8M
Role of basophils in initiating Th2 immune responsesR01AI089771 · NIAID · YALE UNIVERSITY · PI MEDZHITOV, RUSLAN · 2010 to 2014
$2.0M
TOLL RECEPTORS AND CONTROL OF MAMMALIAN IMMUNITYR01AI046688 · NIAID · YALE UNIVERSITY · PI MEDZHITOV, RUSLAN · 2001 to 2005
$1.5M
INTEGRATION OF CYTOKINE RECEPTORS AND IMMUNORECEPTORS SIGNALING PATHWAYSR56AI087725 · NIAID · YALE UNIVERSITY · PI MEDZHITOV, RUSLAN · 2010 to 2010
$414k
Howard Hughes Medical InstituteNIAID NIH HHS 1R56AI087725-01NIAID NIH HHS AI046688NIAID NIH HHS AI055502NIAID NIH HHS AI089771NIAID NIH HHS R01 AI046688NIAID NIH HHS R01 AI055502NIAID NIH HHS R01 AI089771NIAID NIH HHS R37 AI046688NIAID NIH HHS R56 AI087725NIAMS NIH HHS P30 AR053495NIDDK NIH HHS R01 DK071754
6 · The paper itself

Abstract

Diverse cellular responses to external cues are controlled by a small number of signal-transduction pathways, but how the specificity of functional outcomes is achieved remains unclear. Here we describe a mechanism for signal integration based on the functional coupling of two distinct signaling pathways widely used in leukocytes: the ITAM pathway and the Jak-STAT pathway. Through the use of the receptor for interferon-γ (IFN-γR) and the ITAM adaptor Fcγ as an example, we found that IFN-γ modified responses of the phagocytic antibody receptor FcγRI (CD64) to specify cell-autonomous antimicrobial functions. Unexpectedly, we also found that in peritoneal macrophages, IFN-γR itself required tonic signaling from Fcγ through the kinase PI(3)K for the induction of a subset of IFN-γ-specific antimicrobial functions. Our findings may be generalizable to other ITAM and Jak-STAT signaling pathways and may help explain signal integration by those pathways.

Indexed as

AnimalsBacterial LoadCells, CulturedImmunoglobulin Fc FragmentsImmunoreceptor Tyrosine-Based Activation MotifInterferon-gammaInterferon gamma ReceptorJanus Kinase 2ListeriosisMacrophagesMiceMice, Inbred StrainsMice, KnockoutNitric Oxide Synthase Type IIPhagocytosisPhosphoinositide-3 Kinase InhibitorsImmunoglobulin Fc FragmentsInterferon-gammaInterferon gamma ReceptorJak2 protein, mouseJanus Kinase 2Nitric Oxide Synthase Type IINos2 protein, mousePhosphoinositide-3 Kinase InhibitorsReceptors, IgGReceptors, InterferonSTAT1 Transcription Factor

Identifiers

PMID24608040
PMCPMC4137873
OpenAlexW1984029973

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.